Lamivudine/Zidovudine Aurobindo

Lamivudine/Zidovudine, the active ingredient in Lamivudine/Zidovudine Aurobindo, is a nucleoside reverse transcriptase inhibitor presented as an oral tablet for oral use. It treats HIV-1 infection in adults and children, often as part of combination antiretroviral therapy.

GNH USA supplies Lamivudine/Zidovudine Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudine/Zidovudine is an antiretroviral medication that targets HIV replication within the nucleoside reverse transcriptase pathway. - HIV-1 infection (adults): reduces viral load when used in combination regimens. - HIV-1 infection (children): provides pediatric dosing options within fixed‑dose combinations. - Prevention of mother‑to‑child transmission: used during pregnancy to lower transmission risk. - HIV-1 infection (combined therapy): enhances efficacy of other NRTIs and protease inhibitors.

Lamivudine/Zidovudine may cause a range of adverse reactions. Patients should be monitored regularly for any signs of toxicity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Headache: transient cranial discomfort. - Fatigue: general tiredness or weakness. - Diarrhea: loose stools, often self‑limiting.

Serious or Rare Side Effects: - Severe lactic acidosis: metabolic emergency requiring immediate care. - Hepatotoxicity: liver enzyme elevations or hepatitis. - Bone marrow suppression: anemia, neutropenia, or thrombocytopenia. - Hypersensitivity reactions: rash, fever, or organ involvement. - Pancreatitis: abdominal pain with elevated enzymes.

Before prescribing Lamivudine/Zidovudine, clinicians should consider several safety factors. - Renal function: assess and adjust in severe impairment. - Hepatic function: monitor liver enzymes regularly. - Hematologic status: perform baseline and periodic CBC to detect anemia or neutropenia. - Pregnancy: category B; weigh maternal benefits against potential fetal risks. - Drug resistance: avoid using as monotherapy to prevent resistance development. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Lamivudine/Zidovudine can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Didanosine: increased risk of pancreatitis. - Stavudine: heightened mitochondrial toxicity. - Alcohol: may exacerbate hepatotoxic effects.

Moderate Interactions (Monitor Closely): - Nephrotoxic agents: monitor renal function when co‑administered. - Anticoagulants (e.g., warfarin): possible alteration of INR. - Live vaccines: reduced immunogenic response, consider timing of vaccination.